Trial Condition(s):

Atrial Fibrillation

Subtherapeutic INR levels in patients with AVK: incidence, associated factors, prognosis and control strategies (SULTAN)

Bayer Identifier:

17943 Identifier:


EudraCT Number:

Not Available

EU CT Number:

Not Available

Study Completed

Trial Purpose

This prospective observational study is to assess the predictive factors of poor control of international normalized ratio (INR) to determine the treatment strategies received by patients with a poor control of INR in real-life clinical practice and to explore the effectiveness and safety of these strategies in patients with non-valvular atrial fibrillation who start vitamin K antagonist (VKA) treatment

Inclusion Criteria
- Patients aged ≥ 18 years.
- Patients with a diagnosis of nonvalvular atrial fibrillation according to the criteria of the Spanish Agency of Medicines and Medical Devices (AEMPS) (2013) who are treated in cardiology practices.
 - Patients about to start treatment with a vitamin K antagonist or who are in the first two months of treatment.
 - Patients for whom access to at least 80% of INR tests performed during treatment with vitamin K antagonists is expected to be available.
 - Patients with the mental and physical capacity to complete the study questionnaires and give their informed consent to participate in the study.
Exclusion Criteria
-  Patients with mitral stenosis or another significant valve disease for which specific treatment is scheduled or has already been performed (prosthesis or valvuloplasty).
 - Patients hospitalised at the time of inclusion in the study.
 - Patients with a life expectancy of less than 13 months.
 - Patients who are participating in a clinical trial.
 - Patients receiving double antiplatelet therapy.

Trial Summary

Enrollment Goal
Trial Dates
Could I receive a placebo?
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers

Where to Participate


Investigative Site

Many Locations, Spain

Trial Design